38.10

0.40% -0.1525

Castle Biosciences Inc (CSTL)

Overview News Price History Option Chain Financials Why CSTL Down? Discussions Forecast

Castle Biosciences Inc stock is traded at $38.10, with a volume of 274.84K. It is down -0.40% in the last 24 hours and up +9.66% over the past month. Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Previous Close:

$38.25

Open:

$38.25

24h Volume:

274.84K

Relative Volume:

0.71

Market Cap:

$1.11B

Revenue:

$219.79M

Net Income/Loss:

$-57.47M

P/E Ratio:

-17.72

EPS:

-2.15

Net Cash Flow:

$-19.25M

1W Performance:

-3.33%

1M Performance:

+9.66%

6M Performance:

+111.18%

1Y Performance:

+28.58%

1-Day Range:

$37.90

$38.59

1-Week Range:

$37.83

$40.54

52-Week Range:

$14.59

$40.61

Castle Biosciences Inc Stock (CSTL) Company Profile

Name

Castle Biosciences Inc

Sector

Healthcare (1133)

Industry

Diagnostics & Research (54)

Phone

866-788-9007

Address

505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX

Employee

823

Twitter

@castlebio

Next Earnings Date

2024-11-04

Latest SEC Filings

CSTL's Discussions on Twitter

Compare CSTL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CSTL Castle Biosciences Inc	38.10	1.12B	219.79M	-57.47M	-19.25M	-2.15
TMO Thermo Fisher Scientific Inc	566.07	211.55B	43.74B	6.58B	6.11B	17.31
DHR Danaher Corp	224.70	157.68B	24.27B	3.50B	5.02B	4.8589
IDXX Idexx Laboratories Inc	697.06	55.82B	4.17B	1.03B	940.22M	12.61
A Agilent Technologies Inc	141.58	39.81B	6.95B	1.30B	1.15B	4.5714
IQV Iqvia Holdings Inc	220.16	37.14B	15.90B	1.28B	2.21B	7.2842

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Guggenheim	Buy
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Apr-30-21	Initiated	Lake Street	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-27-19	Reiterated	Canaccord Genuity	Buy
Aug-19-19	Initiated	BTIG Research	Buy
Aug-19-19	Initiated	Canaccord Genuity	Buy
Aug-19-19	Initiated	Robert W. Baird	Outperform
Aug-19-19	Initiated	SVB Leerink	Outperform

View All

Castle Biosciences Inc Stock (CSTL) Latest News

08:33 AM

Expert Melanoma Panel Recommends Castle Biosciences DecisionDx-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma - marketscreener.com

08:33 AM

Dec 09, 2025

Castle Biosciences Announces Endorsement of DecisionDx-Melanoma Test in Independent Expert Consensus Paper - Quiver Quantitative

Dec 09, 2025

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma - Yahoo Finance

Dec 09, 2025

Dec 08, 2025

Castle Biosciences (NASDAQ:CSTL) Insider Sells $53,600.17 in Stock - MarketBeat

Dec 08, 2025

Here's Why 'Trend' Investors Would Love Betting on Castle Biosciences (CSTL) - Yahoo Finance

Dec 08, 2025

Dec 07, 2025

New York State Common Retirement Fund Acquires 52,671 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat

Dec 07, 2025

Dec 04, 2025